{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:59:33Z","timestamp":1775037573910,"version":"3.50.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>Carcinosarcoma (CS) is an aggressive form of gynecologic malignancy that accounts for ~5% of carcinomas in the endometrium and ovaries. There has been no significant improvement in survival over the last decades despite additional treatment options. PReferentially Expressed Antigen in MElanoma (PRAME) is an immunotherapy target used for the treatment of several solid tumors. We explored the PRAME protein expression levels in ovarian and uterine CS (n = 29). The expression levels were recorded by H-score (percentage of positively stained cells multiplied by staining intensity) in carcinomatous and sarcomatous components separately and compared by paired t-test. The marker expression levels of ovarian and uterine CS were tested against each other in the CS group. Sarcoma-predominant samples (&gt;50% of the sampled tissue) were compared with samples without predominant sarcomatous components by a 2-sample pooled t-test. In addition, high-grade carcinomatous components of CS samples were tested against low-grade endometrioid carcinoma (International Federation of Gynecology and Obstetrics grades 1 and 2; n = 13), and sarcomatous components against uterine leiomyosarcoma (n = 14). There was no significant difference between any subgroups except for sarcomatous elements of CS and leiomyosarcoma (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). A weak positive correlation was found between H-scores of carcinomatous and sarcomatous components (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.062, <jats:italic toggle=\"yes\">r<\/jats:italic> = 0.36). In the ovarian CS group, there was a moderate inverse correlation between age and the mean H-score of the carcinomatous component (<jats:italic toggle=\"yes\">r<\/jats:italic> = \u22120.683, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.02). Our results further support PRAME overexpression in gynecologic cancers, including CS with similar expression levels in epithelial and mesenchymal components. PRAME might have a role in epithelial-mesenchymal transition in this group of cancers.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000959","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T16:00:39Z","timestamp":1702396839000},"page":"284-289","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["PReferentially Expressed Antigen in MElanoma Expression in Uterine and Ovarian Carcinosarcomas"],"prefix":"10.1097","volume":"43","author":[{"given":"Alaaeddin","family":"Alrohaibani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly M.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathon","family":"Hetts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozlen","family":"Saglam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,11,13]]},"reference":[{"key":"R1-20250802","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1146\/annurev-pathol-020117-043609","article-title":"Molecular genetics of endometrial carcinoma","volume":"14","author":"Bell","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/annonc\/mdw161","article-title":"Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma","volume":"27","author":"Matsuo","year":"2016","journal-title":"Ann Oncol"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/GRF.0b013e31821ac635","article-title":"Uterine carcinosarcoma","volume":"54","author":"El-Nashar","year":"2011","journal-title":"Clin Obstet Gynecol"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ygyno.2020.10.043","article-title":"Uterine carcinosarcoma: contemporary clinical summary, molecular updates, and future research opportunity","volume":"160","author":"Matsuzaki","year":"2021","journal-title":"Gynecol Oncol"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"R6-20250802","first-page":"309","article-title":"Novel targeted therapies in ovarian and uterine carcinosarcomas","volume":"25","author":"Han","year":"2018","journal-title":"Discov Med"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2217\/bmm.12.65","article-title":"The cancer testis antigen PRAME as a biomarker for solid tumor cancer management","volume":"6","author":"Goodison","year":"2012","journal-title":"Biomark Med"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","article-title":"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor","volume":"6","author":"Ikeda","year":"1997","journal-title":"Immunity"},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/modpathol.2013.244","article-title":"Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma","volume":"27","author":"Hemminger","year":"2014","journal-title":"Mod Pathol"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.humpath.2016.12.006","article-title":"Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1","volume":"61","author":"Iura","year":"2017","journal-title":"Hum Pathol"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.jtho.2016.08.120","article-title":"Safety and immunogenicity of the PRAME cancer immunotherapeutic in patients with resected non-small cell lung cancer: a phase I dose-escalation study","volume":"11","author":"Pujol","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1111\/ajco.12586","article-title":"Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non-small cell lung cancer patients","volume":"13","author":"Pan","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cjp2.16","article-title":"Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma","volume":"1","author":"Iura","year":"2015","journal-title":"J Pathol Clin Res"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-007-9643-3","article-title":"Prevalence and prognostic and predictive relevance of PRAME in breast cancer","volume":"109","author":"Doolan","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1159\/000487353","article-title":"Downregulation of prame suppresses proliferation and promotes apoptosis in hepatocellular carcinoma through the activation of the p53-mediated pathway","volume":"45","author":"Zhu","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/PGP.0000000000000864","article-title":"PRAME expression in endometrioid and serous endometrial carcinoma: a potential immunotherapeutic target and possible diagnostic pitfall","volume":"42","author":"Coppock","year":"2023","journal-title":"Int J Gynecol Pathol"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front Immunol"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molonc.2011.02.001","article-title":"The biology of cancer testis antigens: putative function, regulation, and therapeutic potential","volume":"5","author":"Fratta","year":"2011","journal-title":"Mol Oncol"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"D816","DOI":"10.1093\/nar\/gkn673","article-title":"CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens","volume":"37","author":"Almeida","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/gcc.20465","article-title":"Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies","volume":"46","author":"Schenk","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"45352","DOI":"10.18632\/oncotarget.9977","article-title":"PRAME expression and promoter hypomethylation in epithelial ovarian cancer","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"R25-20250802","first-page":"5379","article-title":"Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors","volume":"57","author":"Wada","year":"1997","journal-title":"Cancer Res"},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/PGP.0b013e31827fedef","article-title":"EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma","volume":"32","author":"Saglam","year":"2013","journal-title":"Int J Gynecol Pathol"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12967-018-1757-3","article-title":"PRAME promotes epithelial-to-mesenchymal transition in triple-negative breast cancer","volume":"17","author":"Al-Khadairi","year":"2019","journal-title":"J Transl Med"},{"key":"R28-20250802","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2017.02.010","article-title":"Integrated molecular characterization of uterine carcinosarcoma","volume":"31","author":"Cherniack","year":"2017","journal-title":"Cancer Cell"},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.canlet.2017.06.015","article-title":"Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells","volume":"403","author":"Lee","year":"2017","journal-title":"Cancer Lett"},{"key":"R30-20250802","doi-asserted-by":"crossref","first-page":"e0137476","DOI":"10.1371\/journal.pone.0137476","article-title":"Cancer-testis antigen expression in serous endometrial cancer with loss of X chromosome inactivation","volume":"10","author":"Kang","year":"2015","journal-title":"PLoS One"},{"key":"R31-20250802","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.neo.2016.12.009","article-title":"Whole-genome DNA methylation profiling identifies epigenetic signatures of uterine carcinosarcoma","volume":"19","author":"Li","year":"2017","journal-title":"Neoplasia"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:01:23Z","timestamp":1754161283000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000959","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,13]]}}}